{"name":"Pharnext S.C.A.","slug":"pharnext-s-c-a","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"PXT3003 Intermediate Dose","genericName":"PXT3003 Intermediate Dose","slug":"pxt3003-intermediate-dose","indication":"Other","status":"phase_2"},{"name":"PXT3003 dose 1","genericName":"PXT3003 dose 1","slug":"pxt3003-dose-1","indication":"Charcot-Marie-Tooth disease type 1A (CMT1A)","status":"phase_3"}]}],"pipeline":[{"name":"PXT3003 Intermediate Dose","genericName":"PXT3003 Intermediate Dose","slug":"pxt3003-intermediate-dose","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"PXT3003 dose 1","genericName":"PXT3003 dose 1","slug":"pxt3003-dose-1","phase":"phase_3","mechanism":"PXT3003 is a fixed-dose combination of three active pharmaceutical ingredients that work synergistically to reduce neuroinflammation and promote nerve regeneration in peripheral neuropathies.","indications":["Charcot-Marie-Tooth disease type 1A (CMT1A)"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMingFBVV95cUxNNXJWYjc1WFJIcE11dTV2UHBrWjJZcl95ak16ODF1SU9Ob1lOb2NYeXhfdGlYQTAtSzA1NFFZbDFTcEUyNjJXU3lQOWlsOEdWZmtaRHpLYnJfWFQtZWYxbWp0a2picTJaNDg2TTl0Q0x2dEFvcDRLMVJFVzUzblRVQ0RYUEtHSW1YNnJrdGl1MWtoZC1TSXBfRk1KU1FyUQ?oc=5","date":"2026-02-24","type":"pipeline","source":"Share Talk","summary":"N4 Pharma plc (AIM: N4P) CEO Appointment & Name Change Thalia Therapeutics - Share Talk","headline":"N4 Pharma plc (AIM: N4P) CEO Appointment & Name Change Thalia Therapeutics","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"phase_2":1,"phase_3":1},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}